Updates in immunotherapy for head and neck cancer

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat head and neck cancer. This week we will be joined by Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Ari Rosenberg, MD, University of Chicago, Chicago, IL and Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA.

We will hear about the results of the SAKK 11/16 trial (NCT02999646) of the MVX-ONCO-1 vaccine, a Phase I dose expansion trial (NCT04429542) of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, and increasing T-cell responses in HPV-positive head and neck cancer with TheraT vectors, as well as other novel immunotherapy approaches.

For other head and neck cancer news, head over to our Head and Neck Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.